Chabala JC et al., 1980-10: The paper introducing ivermectin as the semi-synthetic 22,23-dihydro derivative of the natural avermectin B1.
22,23-Dihydroavermectin B1, ivermectin, derived from avermectin B1 by selective hydrogenation using Wilkinson's homogenous catalyst [Ph3P)3RhCl], was shown to be a highly effective drug for the treatment of a wide variety of metazoan parasitic diseases in animals.
1134
Chabala JC et al., 1980-10: The paper introducing ivermectin as the semi-synthetic 22,23-dihydro derivative of the natural avermectin B1. C1 Chabala 1980. Study type: chemistry plus animal efficacy (no human subjects). Country: USA (Merck Sharp & Dohme Research Laboratories). Funder: not stated; all authors Merck employees. Conflicts: none declared. Shows plainly that ivermectin is a chemically modified derivative, not a natural product as isolated. The bracketed catalyst formula is printed that way in the PubMed record (unbalanced parenthesis in the source). Study type: lab.
